Komori
Business alliance4890Tsubota Laboratory IncorporatedPharmaceuticals

Notice of Milestone Achievement and Confirmation of Consideration Receipt Following Submission of the Clinical Study Report for “TLG-001”

The clinical study report for the domestic clinical trial of “TLG-001” was submitted to the co-development partner, fulfilling the contractual milestone. As a result, receipt of a lump-sum payment has been confirmed, and the payment is scheduled to be recognized as revenue in the second quarter of the fiscal year ending March 2027.

Worth reading
30Immaterial
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Impact on Business Performance

The lump-sum payment associated with achievement of this milestone is scheduled to be recognized as revenue in the second quarter of the fiscal year ending March 2027.

Agreements reached under this partnership
ItemDetails
Impact on Business PerformanceThe lump-sum payment associated with achievement of this milestone is scheduled to be recognized as revenue in the second quarter of the fiscal year ending March 2027.
Items this document does not state (22)
Name of alliance partnerAlliance partner's business activitiesAlliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The milestone was fulfilled and receipt of the lump-sum payment was confirmed following submission of the clinical study report to the co-development partner.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Milestone Achievement and Confirmation of Consideration Receipt Following Submission of the Clinical Study Report for “TLG-001” | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori